Original ResearchPublished 12 October 2026Long-term post-trial extension of osilodrostat therapy in selected Canadian patients with Cushing disease from the LINC 3 and LINC 4 programsLuciana Martel-Duguech · Ghislaine Houde · Constance Chik · Syed Ali Imran · André LacroixFrontiers in Endocrinologydoi 10.3389/fendo.2026.1902818